The Synergy Bioabsorbable Polymer Stent System. Credit: Boston Scientific Corporation.

Boston Scientific has announced positive data from the EVOLVE Short DAPT clinical trial of its Synergy Bioabsorbable Polymer (BP) Stent in patients at high bleeding risk after percutaneous coronary intervention.

The trial aimed to determine the safety of a shortened dual antiplatelet therapy (DAPT) duration following treatment with the Synergy stent. Results showed that a three-month DAPT regimen is non-inferior to a 12-month or longer regimen.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

EVOLVE Short DAPT trial involved a total of 2,009 subjects, including 1,487 patients eligible to stop DAPT at three months. Participants received an implant of at least one Synergy stent.

The co-primary endpoints of the trial were the rate of death or myocardial infarction (MI) and the rate of stent thrombosis between three and 15 months. The company noted that both endpoints were met.

According to findings, the rate of death or MI between three and 15 months was non-inferior in patients who received the three-month DAPT versus those on 12-month DAPT.

The rate of stent thrombosis between three and 15 months was 0.3% in the three-month DAPT group, which is said to be considerably lower compared to the endpoint performance goal of 1%.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Boston Scientific executive vice-president and global chief medical officer Ian Meredith said: “We are pleased the study presented today provided robust safety data on shortened DAPT following implantation of the Synergy BP Stent for this patient population, as the reduced length of therapy can be a clinically significant differentiator.

“We continue to build upon the body of evidence supporting the excellent clinical outcomes of the Synergy BP Stent and look forward to submitting these data to regulatory authorities to support an indication for use of this stent in patients at high risk of experiencing a bleeding event.”

Earlier this month, the Synergy Megatron BP Stent received the European CE-Mark.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Awarded for Innovation in Remote Hearing Diagnostics , hearX’s Self Test Kit (STK) delivers clinically validated audiometry via smart devices, enabling remote, scalable hearing assessments in homes, clinics and retail. Learn how hearX is redefining hearing care delivery and reducing costs for providers globally.

Discover the Impact